Interpace Biosciences (OTCMKTS:IDXG) Announces Earnings Results

Interpace Biosciences (OTCMKTS:IDXG) issued its quarterly earnings results on Monday. The business services provider reported $0.01 earnings per share (EPS) for the quarter, Zacks reports. Interpace Biosciences had a return on equity of 219.07% and a net margin of 65.25%.

Interpace Biosciences Stock Performance

Shares of OTCMKTS:IDXG traded up $0.09 during midday trading on Monday, reaching $1.70. 13,703 shares of the company’s stock traded hands, compared to its average volume of 6,815. The company has a fifty day simple moving average of $1.61 and a two-hundred day simple moving average of $1.77. Interpace Biosciences has a 1 year low of $0.77 and a 1 year high of $2.40. The company has a market cap of $7.53 million, a P/E ratio of -34.00 and a beta of 0.61.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.